Samsung BioLogics Records Q2 Operating Profit of 586.4 Billion Won, Up 22.9% Year-over-Year

According to Korea Economic Daily, Samsung BioLogics recorded record operating profit of 586.4 billion won in Q2 2026 (ending June), up 22.9% year-over-year, with sales reaching 1.32 trillion won, a 30.2% increase. The company attributed the strong performance to full-capacity operations at its Songdo plants and favorable exchange rates.

For the first half of 2026, Samsung BioLogics posted sales of 2.58 trillion won and operating profit of 1.17 trillion won, both marking record highs and up 28% year-over-year. Its cumulative contract manufacturing (CMO) orders reached $24.3 billion (approximately 36 trillion won) as of end-June, up from $21.2 billion at end-2025, with orders expected to drive further growth as they undergo minimum three-month production cycles before delivery.